首页期刊导航|癌症生物学与医学（英文版）
期刊信息/Journal information
癌症生物学与医学（英文版）
癌症生物学与医学（英文版）

郝希山

季刊

2095-3941

editor@cancerbiomed.org

022-23522919

300060

天津市河西区体院北环湖西路天津市肿瘤医院C座综合楼三楼

癌症生物学与医学（英文版）/Journal Cancer Biology & MedicineCSCDCSTPCD北大核心SCI
查看更多>>Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:● Cancer epigenetics● Cancer stem cell● Improved in vivo and in vitro cancer models● Cancer prevention and epidemiology● Biomarkers for predicting drug response● Mechanism of drug sensitivity and resistance● New approaches for cancer detection and diagnosis● Oncology clinical trials● Targeted therapy● Multidisciplinary treatment for cancerAuthor benefits: ● Easy online submission via Editorial Manager● Efficient and professional peer-review by expert referees from around the world● Rapid pre-print online publication● No charge for publication and Open Access● International visibility - the journal is available free online
正式出版
收录年代

    Roles of cancer-associated fibroblast functional heterogeneity in shaping the lymphatic metastatic landscape:new insights and therapeutic strategies

    Hanhao ZhengDaiyin LiuZhicong LiuMingjie An...
    445-450页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Immune checkpoint inhibitors:breakthroughs in cancer treatment

    Xueqing KongJinyi ZhangShuwei ChenXianyang Wang...
    451-472页
    查看更多>>摘要：Over the past two decades,immunotherapies have increasingly been considered as first-line treatments for most cancers.One such treatment is immune checkpoint blockade(ICB),which has demonstrated promising results against various solid tumors in clinical trials.Monoclonal antibodies(mAbs)are currently available as immune checkpoint inhibitors(ICIs).These ICIs target specific immune checkpoints,including cytotoxic T-lymphocyte-associated antigen-4(CTLA-4)and programmed cell death protein 1(PD-1).Clinical trial results strongly support the feasibility of this immunotherapeutic approach.However,a substantial proportion of patients with cancer develop resistance or tolerance to treatment,owing to tumor immune evasion mechanisms that counteract the host immune response.Consequently,substantial research focus has been aimed at identifying additional ICIs or synergistic inhibitory receptors to enhance the effectiveness of anti-PD-1,anti-programmed cell death ligand 1(anti-PD-L1),and anti-CTLA-4 treatments.Recently,several immune checkpoint molecular targets have been identified,such as T cell immunoreceptor with Ig and ITIM domains(TIGIT),mucin domain containing-3(TIM-3),lymphocyte activation gene-3(LAG-3),V-domain immunoglobulin suppressor of T cell activation(VISTA),B and T lymphocyte attenuator(BTLA),and signal-regulatory protein α(SIRPα).Functional mAbs targeting these molecules are under development.CTLA-4,PD-1/PD-L1,and other recently discovered immune checkpoint proteins with distinct structures are at the forefront of research.This review discusses these structures,as well as clinical progress in mAbs targeting these immune checkpoint molecules and their potential applications.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants

    Shuyi ChenJing GuKaichun WuXiaodi Zhao...
    473-483页
    查看更多>>摘要：Targeted therapy is crucial for advanced colorectal cancer(CRC)positive for genetic drivers.With advances in deep sequencing technology and new targeted drugs,existing standard molecular pathological detection systems and therapeutic strategies can no longer meet the requirements for careful management of patients with advanced CRC.Thus,rare genetic variations require diagnosis and targeted therapy in clinical practice.Rare gene mutations,amplifications,and rearrangements are usually associated with poor prognosis and poor response to conventional therapy.This review summarizes the clinical diagnosis and treatment of rare genetic variations,in genes including erb-b2 receptor tyrosine kinase 2(ERBB2),B-Raf proto-oncogene,serine/threonine kinase(BRAF),ALK receptor tyrosine kinase/ROS proto-oncogene 1,receptor tyrosine kinase(ALK/ROS1),neurotrophic receptor tyrosine kinases(NTRKs),ret proto-oncogene(RET),fibroblast growth factor receptor 2(FGFR2),and epidermal growth factor receptor(EGFR),to enhance understanding and identify more accurate personalized treatments for patients with rare genetic variations.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Advances in MET tyrosine kinase inhibitors in gastric cancer

    Yifan ZhangLin ShenZhi Peng
    484-498页
    查看更多>>摘要：Gastric cancer is among the most frequently occurring cancers and a leading cause of cancer-related deaths globally.Because gastric cancer is highly heterogenous and comprised of different subtypes with distinct molecular and clinical characteristics,the management of gastric cancer calls for better-defined,biomarker-guided,molecular-based treatment strategies.MET is a receptor tyrosine kinase mediating important physiologic processes,such as embryogenesis,tissue regeneration,and wound healing.However,mounting evidence suggests that aberrant MET pathway activation contributes to tumour proliferation and metastasis in multiple cancer types,including gastric cancer,and is associated with poor patient outcomes.As such,MET-targeting therapies are being actively developed and promising progress has been demonstrated,especially with MET tyrosine kinase inhibitors.This review aims to briefly introduce the role of MET alterations in gastric cancer and summarize in detail the current progress of MET tyrosine kinase inhibitors in this disease area with a focus on savolitinib,tepotinib,capmatinib,and crizotinib.Building on current knowledge,this review further discusses existing challenges in MET alterations testing,possible resistance mechanisms to MET inhibitors,and future directions of MET-targeting therapies.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Revolutionizing tumor immunotherapy:unleashing the power of progenitor exhausted T cells

    Zhang FangXinyi DingHao HuangHongwei Jiang...
    499-512页
    查看更多>>摘要：In exploring persistent infections and malignancies,a distinctive subgroup of CD8+T cells,progenitor exhausted CD8+T(Tpex)cells,has been identified.These Tpex cells are notable for their remarkable self-renewal and rapid proliferation abilities.Recent strides in immunotherapy have demonstrated that Tpex cells expand and differentiate into responsive exhausted CD8+T cells,thus underscoring their critical role in the immunotherapeutic retort.Clinical examinations have further clarified a robust positive correlation between the proportional abundance of Tpex cells and enhanced clinical prognosis.Tpex cells have found noteworthy applications in the formulation of inventive immunotherapeutic approaches against tumors.This review describes the functions of Tpex cells in the tumor milieu,particularly their potential utility in tumor immunotherapy.Precisely directing Tpex cells may be essential to achieving successful outcomes in immunotherapy against tumors.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Decreased LDHB expression in breast tumor cells causes NK cell activation and promotes tumor progression

    Zhihong LuoXiaohua HuangXinyi XuKefeng Wei...
    513-540页
    查看更多>>摘要：Objective:Abnormal metabolism is the underlying reason for breast cancer progression.Decreased lactate dehydrogenase B(LDHB)has been detected in breast cancer but the function of LDHB remains unknown.Methods:Western blot was used to analyze LDHB expression in breast cancer cells.The impact of LDHB on tumor cell migration and invasion was determined using Transwell assays,wound healing assays,and a mouse lung metastasis model.Subcutaneous tumor formation,a natural killer(NK)cell cytotoxicity assay,and flow cytometry evaluated NK cell activation.Immunofluorescence and quantitative real-time PCR detected NK cell activation markers.Kaplan-Meier analysis evaluated the effect of immune cell infiltration on prognosis.Single-sample gene set enrichment analysis determined NK cell activation scores.A support vector machine predicted the role of LDHB in NK cell activation.Results:In this study we showed that LDHB inhibits the breast cancer cell metastasis and orchestrates metabolic reprogramming within tumor cells.Our results revealed that LDHB-mediated lactic acid clearance in breast cancer cells triggers NK cell activation within the tumor microenvironment.Our findings,which were confirmed in a murine model,demonstrated that LDHB in tumor cells promotes NK cell activation and ultimately results in the eradication of malignant cells.Clinically,our study further validated that LDHB affects immune cell infiltration and function.Specifically,its expression has been linked to enhanced NK cell-mediated cytotoxicity and improved patient survival.Furthermore,we identified LDHB expression in tumors as an important predictor of NK cell activation,with strong predictive ability in some cancers.Conclusions:Our results suggest that LDHB is a promising target for activating the tumor immune microenvironment in breast cancer,where LDHB-associated lactic acid clearance leads to increased NK cell activity.This study highlights the critical role of LDHB in regulating immune responses and its potential as a therapeutic target for breast cancer.
      原文链接:
    • NETL
    • NSTL
    • 万方数据